5 Best Performing American Stocks in June 2026

1. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm is awaiting the final two deaths in the ongoing Galinpepimut-S Phase 3 REGAL trial in acute myeloid leukemia patients achieving second complete remission. Alliance Global views the delay in top-line data as a potentially significant positive, since it suggests patients may be living longer than anticipated on Best Available Therapy in the CR2 AML setting.

In May, SELLAS reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. CEO Angelos Stergiou said the first quarter marked an “important period” as SELLAS continued executing across clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout. Stergiou said the upcoming results, triggered by the pre-specified 80th event, will be an “important milestone” for the company. SELLAS said that as of May 11, 2026, 78 events had occurred in the Phase 3 REGAL trial, with the 80th event set to trigger database lock, blinded data review procedures, statistical analysis, unblinding, and disclosure of topline results. The company also initiated an 80-patient Phase 2 trial of SLS009 in newly diagnosed AML patients, with topline data expected in Q4 2026. SELLAS also established an ATM equity offering under its S-3ASR shelf registration, allowing it to raise up to $150 million over time, and said it has not sold any shares through the ATM to date.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) focuses on the development of novel therapeutics for various cancer indications in the United States.

READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term. 

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.